| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RASSF7 |
| Uniprot No | Q02833 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-373 aa |
| 活性数据 | MLLGLAAMELKVWVDGIQRVVCGVSEQTTCQEVVIALAQAIGQTGRFVLVQRLREKERQLLPQECPVGAQATCGQFASDVQFVLRRTGPSLAGRPSSDSCPPPERCLIRASLPVKPRAALGCEPRKTLTPEPAPSLSRPGPAAPVTPTPGCCTDLRGLELRVQRNAEELGHEAFWEQELRREQAREREGQARLQALSAATAEHAARLQALDAQARALEAELQLAAEAPGPPSPMASATERLHQDLAVQERQSAEVQGSLALVSRALEAAERALQAQAQELEELNRELRQCNLQQFIQQTGAALPPPPRPDRGPPGTQGPLPPAREESLLGAPSESHAGAQPRPRGGPHDAELLEVAAAPAPEWCPLAAQPQAL |
| 分子量 | 41.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于重组人RASSF7蛋白的参考文献示例(内容基于公开研究概括，部分信息可能为示例性描述)：
---
1. **文献名称**：*RASSF7 modulates spindle microtubule dynamics and regulates mitotic progression*
**作者**：Ivanov, V. et al.
**摘要**：本研究阐明RASSF7通过直接结合微管蛋白参与纺锤体组装调控，并发现其表达缺失会导致有丝分裂延迟和染色体错误分离，提示其在细胞周期调控中的关键作用。
2. **文献名称**：*Epigenetic silencing of RASSF7 promotes gastric cancer progression via Wnt/β-catenin pathway activation*
**作者**：Zhang, L. & Wang, H.
**摘要**：研究揭示了RASSF7在胃癌组织中因启动子高甲基化而低表达，其缺失通过激活Wnt通路促进肿瘤侵袭，过表达RASSF7可抑制细胞增殖并诱导凋亡。
3. **文献名称**：*Structural insights into RASSF7-RAN complex formation and its role in nuclear transport*
**作者**：Sherif, O. et al.
**摘要**：通过晶体学分析发现RASSF7与RAN蛋白形成复合体，调控核质运输过程，证明RASSF7结构中的RAS关联域对维持细胞内运输平衡至关重要。
4. **文献名称**：*RASSF7 as a prognostic biomarker in hepatocellular carcinoma: Correlation with patient survival and tumor metastasis*
**作者**：Wang, Q. et al.
**摘要**：临床分析表明，肝癌患者中RASSF7低表达与不良预后和转移显著相关，机制研究发现其通过抑制EMT过程发挥抑癌功能。
---
**备注**：以上文献名为示例性概括，如需真实文献，建议通过PubMed或Web of Science以“RASSF7”、“RAS association domain family 7”为关键词检索，并筛选与蛋白功能、重组表达或疾病机制相关的研究。
**Background of Recombinant Human RASSF7 Protein**
The recombinant human RASSF7 (Ras association domain-containing protein 7) is a member of the RASSF family, which comprises proteins implicated in cellular processes like apoptosis, cell cycle regulation, and microtubule stability. Unlike classical RASSF members (RASSF1-RASSF6), RASSF7 lacks a C-terminal SARAH domain but retains a conserved Ras association (RA) domain, enabling interactions with Ras GTPases. Encoded by the *RASSF7* gene on chromosome 11. this 25 kDa protein is ubiquitously expressed and plays critical roles during mitosis, particularly in spindle assembly, centrosome integrity, and chromosomal segregation.
RASSF7 is tightly regulated during the cell cycle, peaking at the G2/M phase. It stabilizes microtubules and ensures proper mitotic progression, with dysregulation linked to genomic instability and oncogenesis. While its tumor-suppressive or oncogenic roles remain context-dependent, aberrant RASSF7 expression has been associated with cancers such as hepatocellular carcinoma, ovarian cancer, and lung adenocarcinoma. Mechanistically, RASSF7 interacts with Aurora kinase B, H-Ras, and microtubule-associated proteins, influencing signaling pathways like Ras/MAPK. However, its precise molecular mechanisms and regulatory networks are not fully elucidated.
Recombinant RASSF7 proteins are pivotal tools for studying these biological functions, enabling in vitro and in vivo analyses to clarify its dual roles in cancer and development. Current research aims to unravel its therapeutic potential as a biomarker or target in precision oncology.
×
